T细胞受体
医学
过继性细胞移植
免疫疗法
嵌合抗原受体
癌症研究
细胞疗法
T细胞
肿瘤微环境
免疫学
免疫系统
细胞
肿瘤细胞
化学
生物化学
作者
Estelle Baulu,Aurore Dougé,Nicolas Chuvin,Jacques‐Olivier Bay,Stéphane Depil
标识
DOI:10.1016/j.bulcan.2021.06.004
摘要
In solid tumors, adoptive T cell therapies based on ex vivo amplification of antitumor T cell are represented by three main complementary approaches : (i) tumor infiltrating lymphocytes (TILs) which are amplified in vitro before reinjection to the patient, (ii) chimeric antigen receptor (CAR) engineered T cells and (iii) T cell receptor (TCR) engineered T cells. Despite encouraging results, some obstacles remain, such as optimal target selection and tumor microenvironment. In this Review, we discuss pros and cons of these different therapeutic strategies that may open new perspectives in the treatment of solid tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI